BridgeBio presents data from ATTRibute-CM

BridgeBio (BBIO) Pharma presented data from ATTRibute-CM, highlighting the reduced incidence of atrial fibrillation events in the overall ATTR-CM population. These data were presented in a moderated ePoster at the Annual Congress of the Heart Failure Association of the ESC, taking place in Belgrade, Serbia from May 17 – 20, 2025. In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup with no prior history of AF compared to placebo In the ATTRibute-CM study, acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date in both ATTRv-CM and ATTRwt-CM patients: In as few as 3 months, the time to first event durably separated relative to placebo; A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30; A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30. Acoramidis is approved as Attruby by the U.S. FDA and is approved as BEYONTTRA by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency and UK Medicines and Healthcare Products Regulatory Agency